Ampio Pharmaceuticals Spins-Off Sexual Dysfunction Business

Ampio Pharmaceuticals (NYSE MKT:

) today announced that it has spun off its sexual dysfunction business into a standalone company called Vyrix Pharmaceuticals, Inc. The new Company is expected to be funded through an initial public offering. Vyrix' assets will include Zertane and Zertane-ED, late stage men's health products from Ampio's portfolio. Vyrix' initial business strategy is to initiate and complete registration trials for Zertane in the US and develop worldwide commercialization and marketing partnerships. The Company will work to build awareness of PE in the US with the intention of paving the way for successful product introduction and initiate pre-clinical work on Zertane-ED, a potential combination treatment for premature ejaculation and erectile dysfunction.